Across TCGA pan-cancer cohorts, RPL23AP38 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL23AP38’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RPL23AP38 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP38 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, PAAD, and COAD are the cancer types where RPL23AP38 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP38 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.059	.005	4	view →
PAAD	Male	All	+0.255	.018	2	view →
COAD	All	All	+0.191	.018	2	view →
KICH	Female	II,III,IV	−0.107	.026	2	view →
THCA	Female	II,III,IV	+0.128	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL23AP38 RNA expression & survival · all RPL23AP38 data types